On Monday, Shares of Southwestern Energy Company (NYSE:SWN), subtract -0.80% and closed at $13.71 in the last trading session. The last trading range of the stock ranges between $13.68 and $14.38. The company’s Market capitalization is $6.65 Billion with the total Outstanding Shares of 493.646 million. During the 52-week trading session the minimum price at which share price traded, registered at $5.00 and reached to max level of $15.59. In conjunction with Southwestern Energy Company’s 2016 Third Quarter earnings release, you are invited to listen to its conference call that will be broadcast live over the Internet on Friday, October 21, 2016, at 10:00 a.m. EDT with Bill Way, President and Chief Executive Officer of Southwestern Energy Company.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), jumped 5.90% and closed at $14.19 in the last trading session. The last trading range of the stock ranges between $13.64 and $14.34. The company’s Market capitalization is $2.74 Billion with the total Outstanding Shares of 192.71 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.37 and reached to max level of $14.34. ARIAD Pharmaceuticals, Inc. (ARIA) recently declared updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
The updated Phase 1/2 results were included in a poster presentation on Sunday, October 9 at the 41st Annual Congress of the European Society for Medical Oncology (ESMO) held in Copenhagen, Denmark.
Phase 1/2 Study
The data presented at ESMO include safety analyses on all patients in the trial (N=137) and efficacy analyses on all patients with ALK+ NSCLC (n=79). Of the 79 ALK+ NSCLC patients, all but eight had failed prior crizotinib therapy. The presentation is based on patient data as of May 2016 with a median time on brigatinib treatment for ALK+ NSCLC patients of 20.0 months (range, 0.03 – 47.4 months, ongoing). Patient enrollment in the trial is complete, with the last patient enrolled in July 2014.
“The long-term follow up on this clinical trial of brigatinib continues to show anti-tumor activity with a confirmed overall objective response rate of 62 percent in crizotinib-resistant ALK-positive NSCLC patients at all doses evaluated, and 76 percent among those patients who received the 180 mg dose regimen with a seven-day lead-in at 90 mg once daily,” stated Lyudmila A. Bazhenova, M.D., a clinical professor of medicine at the University of California San Diego Moores Cancer Center. “The median progression-free survival in this post-crizotinib ALK+ NSCLC patient group continues to exceed one year.”